Document is current
Any future updates will be listed below
-
Authors
Bergersen, Kristina V.
Zheng, Ying
Rossetti, Maura
Ruffin, Felicia
Pickering, Harry
Parmar, Rajesh
Sunga, Gemalene
Chan, Liana C.
Gjertson, David
Fowler, Vance G.
Yeaman, Michael R.
Reed, Elaine F.
,
Hoffmann, Alexander
Medie, Felix
Sharma, Batu
Thaden, Joshua
-
Funding
Funding for this research was provided by:
National Institute of Diabetes and Digestive and Kidney Diseases (TL1DK132768)
National Institute of Allergy and Infectious Diseases (U01AI124319, U01AI124319, U01AI124319)
- License Information
-
More Information
Article History
Received: 13 November 2024
Accepted: 7 February 2025
First Online: 18 February 2025
Declarations
:
: This study was conducted in accordance with Good Clinical Practice and Human Subjects Research as previously approved by the Duke University Medical Center (DUMC) Institutional Review Board (Approval Number: Pro00008031). The patients for this study were selected from and prospectively enrolled via an informed consent process under the Duke Institutional Review Board (IRB) Protocol # Pro00008031 between 2007 and 2017. If a patient died, written informed consent for participation in this study was provided by the participants’ legal guardians/next of kin.
: Not applicable.
: VGF reports Grant/ Research Support: MedImmune, Cerexa/Forest/Actavis/Allergan, Pfizer, Advanced Liquid Logics, Theravance, Novartis, Cubist/Merck; Medical Biosurfaces; Locus; Affinergy; Contrafect; Karius; Genentech, Regeneron, BasileaPaid Consultant: Pfizer, Novartis, Galderma, Novadigm, Durata, Debiopharm, Genentech, Achaogen, Affinium, Medicines Co., Cerexa, Tetraphase, Trius, MedImmune, Bayer, Theravance, Cubist, Basilea, Affinergy, Janssen, xBiotech, Contrafect, Regeneron, Basilea, Destiny. Membership: Merck Co-Chair V710 Vaccine. Educational fees: Green Cross, Cubist, Cerexa, Durata, Theravance; Debiopharm. Royalties: UpToDate.M.R.Y is a founder and shareholder of NovaDigm Therapeutics, Inc. which develops anti-infective vaccines and immunotherapies targeting S. aureus and other pathogens. He holds patents on anti-infectives, vaccines and immunotherapeutics targeting infectious diseases, including those caused by S. aureus.
